Microprojection array with improved skin adhesion and compliance

• US 20060051403A1
• Filed: 09/07/2005
• Published: 03/09/2006
• Est. Priority Date: 09/08/2004
• Status: Abandoned Application

• Current Assignee: ALZA Corporation (Johnson & Johnson)
• Original Assignee: ALZA Corporation (Johnson & Johnson)
• Inventors: Daddona, Peter, Cormier, Michel J.N., Matriano, James
• Application Number:
  US11/222,297
• Publication Number:
  US 20060051403A1
• Time in Patent Office: Days
• US Class Current: 424/448
• CPC Class Codes: A61K 9/0021 Intradermal administration, e.g. through microneedle arrays, needleless injectors mechanical aspects A61M
• CPC Class Codes: A61K 9/703 characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
• CPC Class Codes: A61K 9/7084 Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
• CPC Class Codes: A61M 2037/0023 Drug applicators using microneedles
• CPC Class Codes: A61M 2037/0046 Solid microneedles
• CPC Class Codes: A61M 37/0015 by using microneedles

Abstract

A transdermal delivery system having a microprojection array with one or more voids configured to allow an adhesive backing to attach to a user'"'"'s skin and, hence, improve retention of the system thereto. Radial voids can be configured to enhance compliance of the array to conform more readily to non-flat areas of the skin.

Claims

1. A device for transdermally delivering a pharmacologically active agent, the device comprising:

a member having a plurality of stratum corneum-piercing microprojections;

at least one active agent adapted to be delivered transdermally by the microprojections; and

at least one void in the member that allows an adhesive backing to communicate through the void.

2. The device of claim 1, wherein the device includes an adhesive backing that allows the adhesive backing to communicate though the at least one void.

3. The device of claim 1, wherein the active agent is coated on at least one of the microprojections.

4. The device of claim 1, wherein the void enables a reduction in the peripheral adhesive area outside the member.

5. The device of claim 1, wherein the void increases the access of an adhesive backing enabling increased uniformity of adhesion across the member.

6. The device of claim 1, wherein the member has substantially uniform adhesion characteristics across the surface of the member.

7. The device of claim 1, wherein the void is substantially circular.

8. The device of claim 1, wherein the void has a total area greater than approximately 3 cm².

9. The device of claim 1, wherein the void has a surface area greater than approximately 0.2 mm².

10. The device of claim 1, wherein the void is at least approximately 2 mm as measured across its widest length.

11. The device of claim 1, wherein the member has a plurality of voids.

12. The device of claim 1, wherein the member has a total void area in the range of approximately 5-50% of the total member area.

13. The device of claim 1, wherein the member has a total area greater than approximately 1 cm².

14. The device of claim 1, wherein the member has at least one radial void that extends from a central portion of the member to the periphery.

15. The device of claim 1, wherein the void divides the member into at least two subunits.

16. The device of claim 1, wherein the member is separated into two subunits and the void is configured as substantially circular.

17. The device of claim 1, wherein the member has an area of about 3 cm² and a diameter of about 2 cm.

18. The device of claim 1, wherein the void has a diameter of about 0.7 cm, a void area of about 0.39 cm² and ratio of void area to member of approximately 14.9%.

19. The device of claim 1, wherein the void has a diameter of about 0.49 cm, a void area of about 0.18 cm² and ratio of void area to member of approximately 6.6%.

20. The device of claim 1, wherein the member has a plurality of voids having diameters of about 0.24 cm, a void area of about 0.33 cm² and ratio of void area to member of approximately 12.3%.

21. The device of claim 1, wherein the member has a plurality of voids having diameters of about 0.33 cm, a void area of about 0.43 cm² and ratio of void area to member of approximately 16.9%.

22. The device of claim 2, wherein the backing comprises a thin flexible sheet consisting of polymeric material that is optionally perforated.

23. The device of claim 1, wherein the member has a plurality of stratum corneum-piercing microprojections.

24. The device of claim 1, wherein said array is manufactured from a metal consisting of the group of stainless steel, titanium, nickel titanium alloys, or similar biocompatible materials.

25. The device of claim 1, wherein said coating comprises an antigenic agent.

26. A device for transdermally delivering a pharmacologically active agent, the device comprising:

a member having a plurality of stratum corneum-piercing microprojections;

at least one active agent coated on at least one of the microprojections;

at least one void in the member; and

an adhesive backing that allows the adhesive backing to communicate with a subject through the at least one void enabling increased uniformity of adhesion across the member.

27. A method of transdermally delivering a pharmacologically active agent, the method comprising:

providing a delivery system having a microprojection member that includes a plurality of stratum corneum-piercing microprojections, at least one active agent adapted to be delivered transdermally by the microprotrusions, an adhesive backing, and at least one void in the member to allow the adhesive backing to communicate through the void; and

applying the member to a surface so that the adhesive backing communicates with the surface through the void.

28. The method of claim 27, wherein the active agent is coated on at least one microprojection.